Monty Allen Sells 1,419 Shares of iRadimed (NASDAQ:IRMD) Stock

iRadimed Corporation (NASDAQ:IRMD) Director Monty Allen sold 1,419 shares of iRadimed stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $86.41, for a total value of $122,615.79. Following the completion of the transaction, the director owned 19,581 shares of the company’s stock, valued at approximately $1,691,994.21. This represents a 6.76% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

iRadimed Trading Down 1.0%

NASDAQ IRMD opened at $83.56 on Thursday. The stock has a market capitalization of $1.07 billion, a price-to-earnings ratio of 46.68 and a beta of 0.89. The stock has a 50-day moving average of $91.48 and a 200 day moving average of $93.25. iRadimed Corporation has a twelve month low of $67.84 and a twelve month high of $107.90.

iRadimed (NASDAQ:IRMD) last posted its quarterly earnings data on Friday, July 31st. The medical equipment provider reported $0.46 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.02. iRadimed had a return on equity of 23.45% and a net margin of 26.70%.The business had revenue of $20.47 million during the quarter, compared to analysts’ expectations of $20.35 million. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. Equities analysts predict that iRadimed Corporation will post 1.98 EPS for the current fiscal year.

iRadimed Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 28th. Shareholders of record on Friday, August 14th were issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend was Friday, August 14th. iRadimed’s dividend payout ratio (DPR) is presently 44.69%.

Institutional Investors Weigh In On iRadimed

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada grew its holdings in shares of iRadimed by 14.7% during the first quarter. Royal Bank of Canada now owns 25,782 shares of the medical equipment provider’s stock worth $1,354,000 after buying an additional 3,307 shares in the last quarter. AQR Capital Management LLC lifted its stake in shares of iRadimed by 7.5% in the first quarter. AQR Capital Management LLC now owns 15,829 shares of the medical equipment provider’s stock worth $831,000 after buying an additional 1,108 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of iRadimed by 5.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock worth $252,000 after buying an additional 234 shares in the last quarter. Jones Financial Companies Lllp boosted its position in iRadimed by 8,568.5% during the first quarter. Jones Financial Companies Lllp now owns 11,269 shares of the medical equipment provider’s stock worth $591,000 after acquiring an additional 11,139 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in iRadimed by 1.1% during the first quarter. Goldman Sachs Group Inc. now owns 169,387 shares of the medical equipment provider’s stock worth $8,889,000 after acquiring an additional 1,821 shares during the last quarter. Institutional investors and hedge funds own 92.34% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on IRMD. Wall Street Zen downgraded shares of iRadimed from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings cut iRadimed from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $120.00.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.